Iclusig Dosage & Drug Information

Concise Prescribing Info

Contents

Ponatinib

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Indications/Uses

Adults w/ chronic, accelerated or blast phase chronic myeloid leukaemia who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib & for whom subsequent treatment w/ imatinib is not clinically appropriate; or who have T315I mutation. Adults w/ Philadelphia chromosome +ve acute lymphoblastic leukaemia who are resistant to dasatinib; who are intolerant to dasatinib & for whom subsequent treatment w/ imatinib is not clinically appropriate; or who have T315I mutation.

Dosage/Direction for Use

Adult Recommended starting dose: 45 mg once daily. Dose modifications may be required during treatment.

Administration

May be taken with or without food: Swallow whole, do not crush/dissolve.

Contraindications

Hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01EA05 - ponatinib ; Belongs to the class of BCR-ABL tyrosine kinase inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Iclusig FC tab 15 mg

Packing/Price

1's

Iclusig

ponatinib

Manufacturer:

Otsuka